

Substitute for Form 1449 A & B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/598,533
Confirmation Number	6983
Filing Date	September 1, 2006
First Named Inventor	Yoshinobu YAMAZAKI
Art Unit	1614
Examiner Name	Not Yet Assigned
Attorney Docket Number	Q96716

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
		US 5,994,294		11-30-1999	Garvey et al.
		US 6,294,517	B1	09-25-2001	Garvey et al.
		US 5,932,538		06-03-1999	Garvey, et al.
		US 2004/072851	A1	04-15-2004	Shimoyama et al.
		US 2006/001899	A1	01-26-2006	Nagayama et al.
		US 2006/0142374	A1	06-29-2006	Tsuro et al.
		US 2002/143007	A1	10-03-2002	Garvey, et al.

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁴
		Country Code ³	Number ⁴	Kind Code ² (if known)			
		JP	2001-288115	A	10-16-2001	Yamanouchi Pharmaceutical Co., Ltd.	Abstract
		JP	2000-247998	A	09-12-2000	Kissei Pharmaceutical Co., Ltd.	Abstract
		WO	99/15202	A1	04-1-1999	Kissei Pharmaceutical Co., Ltd.	Abstract
		WO	99/48530	A1	09-30-1999	Merck & Co., Inc.	English
		WO	2004/054574	A1	07-01-2004	Kissei Pharmaceutical Co., Ltd.	Abstract
		WO	2004/022538	A1	03-18-2004	Kissei Pharmaceutical Co., Ltd.	Abstract

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume(issue number), publisher, city, and/or country where published.	Translation ⁴
		SHIZUO YAMADA, et al.; <i>IN VIVO</i> Receptor Binding of Novel α_1 -Adrenoceptor Antagonists for Treatment of Benign Prostatic Hyperplasia; <i>Life Science</i> , 1998, Vol. 62, Nos. 17/18, pp. 1585-1589	English
		T. OKURA; Selective and sustained occupancy of Prostatic α_1 -Adrenoceptors by oral administration of KMD-3213 and its plasma concentration in rats; <i>JPP</i> 2002, 54; No. 7, 975-982	English
		K. AKIYAMA, et al.; Effects of KMD-3213, a Uroselective α_1 -Adrenoceptor Antagonist, on the Tilt-Induced Blood Pressure Response in Normotensive Rats; <i>Jpn J. Pharmacol.</i> 90, No. 2, 131-137 (2002)	English
		Teruhisa OHASHI; <i>Gekkan Hodanren</i> , 1998, No. 591, pp. 57-60	No
		Folia Pharmacologica Japonica, 2003, Vol. 121, No. 5, pp. 307-316;	English
		Osamu ISHIZUKA; <i>Ceriatr Med</i> , 2003, Vol. 41, No. 8, pp. 1149-1153	No
		O. ISHIZUKA; Micthritation in conscious rats with and without bladder outlet obstruction: role of spinal α_1 -adrenoceptors; <i>Br. J. Pharmacol.</i> , 1996, Vol. 117, No. 5, pp. 962-966	English

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the instant. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.